Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
AssigneeThe UAB Research Foundation
InventorsJ. Edwin Blalock, Uros V. Djekic, Patricia L. Jackson, Amit Gaggar, Brett Noerager, Philip J. O'Reilly
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for reducing or preventing neutrophilic inflammation in a subject comprising selecting a subject with or at risk for neutrophilic inflammation and administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase. Provided herein are also methods for treatment or prevention of diseases associated with neutrophilic inflammation.
Claims28
A method for reducing neutrophilic inflammation in a subject comprising:
- (a) selecting a subject with neutrophilic inflammation;
- and
- (b) administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase, wherein the agent that inhibits the expression or activity of prolyl endopeptidase is selected from the group consisting of a proline derivative, a pyrrolidineamide derivative, a prolinal derivative, a sulfated chitooligosaccharide, a plant phenolic, eurystatin, an inhibitory peptide, and an inhibitory nucleic acid, wherein, if the agent is a plant phenolic, the plant phenolic is selected from the group consisting of 1,2,3-trigalloyl glucopyranoside, 1,2,6-trigalloyl glucopyranoside, 1,2,3,4,6- pentagalloyl gluco-pyranoside, 1,2,6-trigalloyl alloside, 1,3,6-trigalloyl alloside, 1,2,3,6-tetragalloyl alloside, acetonyl geraniin, corilagin, elaeocarpusin, euphorscopin, geraniin, helioscopin B, helioscopinin A, helioscopinin B, jolkinin, macranganin, rugosin E, supinanin, and teracatain.
A method of treating neutrophilic inflammation or a disease associated with neutrophilic inflammation in a subject, comprising:
- (a) obtaining a biological sample from the subject;
- and
- (b) determining the level of expression or activity of PE in the sample, wherein an increase in expression or activity of PE as compared to a control indicates the subject has neutrophilic inflammation or a disease associated with neutrophilic inflammation;
- and
- (c) administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase if the subject has neutrophilic inflammation or a disease associated with neutrophilic inflammation, wherein the agent that inhibits the expression or activity of prolyl endopeptidase is selected from the group consisting of a proline derivative, a pyrrolidineamide derivative, a prolinal derivative, a sulfated chitooligosaccharide, a plant phenolic, eurystatin, an inhibitory peptide, and an inhibitory nucleic acid.
Dependencies are inferred from the claim text.